Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical model

Background: Mycoplasma genitalium (MG) causes a sexually transmitted infection (STI) with a rising rate of antimicrobial resistance. Currently, guidelines do not recommend screening asymptomatic men who have sex with men (MSM). We developed a mathematical model of MG transmission to examine the impa...

Full description

Bibliographic Details
Main Authors: Jason J. Ong, Luanqi Ruan, Aaron G. Lim, Catriona S. Bradshaw, David Taylor-Robinson, Magnus Unemo, Patrick J. Horner, Peter Vickerman, Lei Zhang
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:EClinicalMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537021000596
_version_ 1818416818269716480
author Jason J. Ong
Luanqi Ruan
Aaron G. Lim
Catriona S. Bradshaw
David Taylor-Robinson
Magnus Unemo
Patrick J. Horner
Peter Vickerman
Lei Zhang
author_facet Jason J. Ong
Luanqi Ruan
Aaron G. Lim
Catriona S. Bradshaw
David Taylor-Robinson
Magnus Unemo
Patrick J. Horner
Peter Vickerman
Lei Zhang
author_sort Jason J. Ong
collection DOAJ
description Background: Mycoplasma genitalium (MG) causes a sexually transmitted infection (STI) with a rising rate of antimicrobial resistance. Currently, guidelines do not recommend screening asymptomatic men who have sex with men (MSM). We developed a mathematical model of MG transmission to examine the impact of various screening strategies on the incidence and prevalence of MG among MSM attending a sexual health clinic. Methods: A compartmental mathematical model of MG transmission among MSM was constructed and calibrated using data from the Melbourne Sexual Health center, where resistance-guided therapy provides high treatment effectiveness (92–95%). The model stratified men by symptom status, sexual risk behaviours and whether or not they had MG with macrolide resistance. We simulated the impact on endemic steady-state MG prevalence and incidence of the following screening scenarios, namely screening: 1) no MSM; 2) only symptomatic MSM (the current recommendation); 3) all symptomatic and high-risk asymptomatic MSM; and 4) all MSM. Our base case analysis assumed a treatment effectiveness of 92–95% using resistance-guided therapy. We also examined the impact of treatment effectiveness (i.e. the proportion of detected MG that were cured) and screening coverage (i.e. testing rate) on MG prevalence. Findings: The model predicts that the overall endemic MG prevalence is 9.1% (95% CI: 7.9–10.0) in the current situation where screening is only offered to symptomatic MSM (base-case). This would increase to 11·4% (95% confidence intervals (CI): 10.2–13.7) if no MSM are offered screening, but would decrease to 7.3% (95% CI: 5.7–8.4) if all symptomatic and high-risk asymptomatic MSM were offered screening and 6.4% (95% CI: 4.7–7·7) if all MSM were offered screening. Increasing coverage of MSM screening strategies shows a similar effect on decreasing endemic MG incidence. When evaluating the simultaneous impact of treatment effectiveness and screening coverage, we found that offering screening to more MSM may reduce the overall prevalence but leads to a higher proportion of macrolide-resistant MG, particularly when using treatment regimens with lower effectiveness. Interpretation: Based on the available treatment options, offering screening for MG to other MSM (beyond the currently recommended group of symptomatic MSM) could slightly reduce the prevalence and incidence of MG. However, further increasing screening coverage must be weighed against the impact of lower treatment effectiveness (i.e. when not using resistance-guided therapy), increasing the selection of macrolide resistance, and other negative consequences related to AMR and management (e.g. unnecessary psychological morbidity from infections that do not need treatment).
first_indexed 2024-12-14T11:56:56Z
format Article
id doaj.art-0c05f8388eef4fea916701a5e0efbbf2
institution Directory Open Access Journal
issn 2589-5370
language English
last_indexed 2024-12-14T11:56:56Z
publishDate 2021-03-01
publisher Elsevier
record_format Article
series EClinicalMedicine
spelling doaj.art-0c05f8388eef4fea916701a5e0efbbf22022-12-21T23:02:05ZengElsevierEClinicalMedicine2589-53702021-03-0133100779Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical modelJason J. Ong0Luanqi Ruan1Aaron G. Lim2Catriona S. Bradshaw3David Taylor-Robinson4Magnus Unemo5Patrick J. Horner6Peter Vickerman7Lei Zhang8Central Clinical School, Monash University, Victoria, Melbourne, Australia; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China; Corresponding authors.China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China; Research Base of Key Laboratory of Surveillance and Early Warning on Infectious Disease, Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, ChinaPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United KingdomCentral Clinical School, Monash University, Victoria, Melbourne, AustraliaFaculty of Medicine, Imperial College London, London, United KingdomWHO Collaborating Centre for Gonorrhoea and other STIs, Örebro University, Örebro, SwedenPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United KingdomPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United KingdomCentral Clinical School, Monash University, Victoria, Melbourne, Australia; China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China; Artificial Intelligence and Modelling in Epidemiology Program, Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia; Corresponding authors.Background: Mycoplasma genitalium (MG) causes a sexually transmitted infection (STI) with a rising rate of antimicrobial resistance. Currently, guidelines do not recommend screening asymptomatic men who have sex with men (MSM). We developed a mathematical model of MG transmission to examine the impact of various screening strategies on the incidence and prevalence of MG among MSM attending a sexual health clinic. Methods: A compartmental mathematical model of MG transmission among MSM was constructed and calibrated using data from the Melbourne Sexual Health center, where resistance-guided therapy provides high treatment effectiveness (92–95%). The model stratified men by symptom status, sexual risk behaviours and whether or not they had MG with macrolide resistance. We simulated the impact on endemic steady-state MG prevalence and incidence of the following screening scenarios, namely screening: 1) no MSM; 2) only symptomatic MSM (the current recommendation); 3) all symptomatic and high-risk asymptomatic MSM; and 4) all MSM. Our base case analysis assumed a treatment effectiveness of 92–95% using resistance-guided therapy. We also examined the impact of treatment effectiveness (i.e. the proportion of detected MG that were cured) and screening coverage (i.e. testing rate) on MG prevalence. Findings: The model predicts that the overall endemic MG prevalence is 9.1% (95% CI: 7.9–10.0) in the current situation where screening is only offered to symptomatic MSM (base-case). This would increase to 11·4% (95% confidence intervals (CI): 10.2–13.7) if no MSM are offered screening, but would decrease to 7.3% (95% CI: 5.7–8.4) if all symptomatic and high-risk asymptomatic MSM were offered screening and 6.4% (95% CI: 4.7–7·7) if all MSM were offered screening. Increasing coverage of MSM screening strategies shows a similar effect on decreasing endemic MG incidence. When evaluating the simultaneous impact of treatment effectiveness and screening coverage, we found that offering screening to more MSM may reduce the overall prevalence but leads to a higher proportion of macrolide-resistant MG, particularly when using treatment regimens with lower effectiveness. Interpretation: Based on the available treatment options, offering screening for MG to other MSM (beyond the currently recommended group of symptomatic MSM) could slightly reduce the prevalence and incidence of MG. However, further increasing screening coverage must be weighed against the impact of lower treatment effectiveness (i.e. when not using resistance-guided therapy), increasing the selection of macrolide resistance, and other negative consequences related to AMR and management (e.g. unnecessary psychological morbidity from infections that do not need treatment).http://www.sciencedirect.com/science/article/pii/S2589537021000596
spellingShingle Jason J. Ong
Luanqi Ruan
Aaron G. Lim
Catriona S. Bradshaw
David Taylor-Robinson
Magnus Unemo
Patrick J. Horner
Peter Vickerman
Lei Zhang
Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical model
EClinicalMedicine
title Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical model
title_full Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical model
title_fullStr Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical model
title_full_unstemmed Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical model
title_short Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical model
title_sort impact of screening on the prevalence and incidence of mycoplasma genitalium and its macrolide resistance in men who have sex with men living in australia a mathematical model
url http://www.sciencedirect.com/science/article/pii/S2589537021000596
work_keys_str_mv AT jasonjong impactofscreeningontheprevalenceandincidenceofmycoplasmagenitaliumanditsmacrolideresistanceinmenwhohavesexwithmenlivinginaustraliaamathematicalmodel
AT luanqiruan impactofscreeningontheprevalenceandincidenceofmycoplasmagenitaliumanditsmacrolideresistanceinmenwhohavesexwithmenlivinginaustraliaamathematicalmodel
AT aaronglim impactofscreeningontheprevalenceandincidenceofmycoplasmagenitaliumanditsmacrolideresistanceinmenwhohavesexwithmenlivinginaustraliaamathematicalmodel
AT catrionasbradshaw impactofscreeningontheprevalenceandincidenceofmycoplasmagenitaliumanditsmacrolideresistanceinmenwhohavesexwithmenlivinginaustraliaamathematicalmodel
AT davidtaylorrobinson impactofscreeningontheprevalenceandincidenceofmycoplasmagenitaliumanditsmacrolideresistanceinmenwhohavesexwithmenlivinginaustraliaamathematicalmodel
AT magnusunemo impactofscreeningontheprevalenceandincidenceofmycoplasmagenitaliumanditsmacrolideresistanceinmenwhohavesexwithmenlivinginaustraliaamathematicalmodel
AT patrickjhorner impactofscreeningontheprevalenceandincidenceofmycoplasmagenitaliumanditsmacrolideresistanceinmenwhohavesexwithmenlivinginaustraliaamathematicalmodel
AT petervickerman impactofscreeningontheprevalenceandincidenceofmycoplasmagenitaliumanditsmacrolideresistanceinmenwhohavesexwithmenlivinginaustraliaamathematicalmodel
AT leizhang impactofscreeningontheprevalenceandincidenceofmycoplasmagenitaliumanditsmacrolideresistanceinmenwhohavesexwithmenlivinginaustraliaamathematicalmodel